) mm Hg, range 37-67 mm Hg), and systemic hypertension alone (160.7 (5-9)/100-6 (3.2) mm Hg) was present in 11 patients. Both conditions were present in 12 patients, while 11 patients had systemic sclerosis without pulmonary or systemic hypertension. There were no significant differences in plasma ET-1 levels between patients with pulmonary hypertension alone (1*62 (0.21) pg/ml) and those with systemic hypertension alone (1*65 (0.43) pg/ml). In particular, patients with normal pulmonary artery and systemic pressures (n = 11) had plasma ET-1 concentrations identical to those found in patients (n =12) with both pulmonary and systemic hypertension (1.70 (0.15) v 1-64 (0.35) pg/ml, respectively). No correlations were observed between plasma ET-1 and either pulmonary or systemic pressures. Conclusion-Systemic sclerosis is characterised by increased plasma ET-1 levels, but neither pulmonary nor systemic hypertension are accompanied by fiuther increase in plasma peptide levels. (Ann Rheum Dis 1995; 54: 730-734) 
alone was present in 14 patients with systemic sclerosis (50. 5 (8.49 ) mm Hg, range 37-67 mm Hg), and systemic hypertension alone (160.7 (5-9)/100-6 (3.2) mm Hg) was present in 11 patients. Both conditions were present in 12 patients, while 11 patients had systemic sclerosis without pulmonary or systemic hypertension. There were no significant differences in plasma ET-1 levels between patients with pulmonary hypertension alone (1*62 (0.21) pg/ml) and those with systemic hypertension alone (1*65 (0.43) pg/ml). In particular, patients with normal pulmonary artery and systemic pressures (n = 11) had plasma ET-1 concentrations identical to those found in patients (n =12) with both pulmonary and systemic hypertension (1.70 (0.15) v 1-64 (0.35) pg/ml, respectively). No correlations were observed between plasma ET-1 and either pulmonary or systemic pressures. Conclusion-Systemic sclerosis is characterised by increased plasma ET-1 levels, but neither pulmonary nor systemic hypertension are accompanied by fiuther increase in plasma peptide levels.
(Ann Rheum Dis 1995; 54: [730] [731] [732] [733] [734] Systemic sclerosis (SSc) is known to be characterised by functional disorders of the regulation of microvascular blood flow, increased vascular resistance, and progressive perivascular fibrosis of the skin and visceral organs.' The lungs are often clinically involved,2 3 and pulmonary hypertension is a frequent cause of death.4 Systemic hypertension is also common, both in the presence and in the absence of SSc-related kidney damage. 5 Increased plasma concentrations of the most potent endothelium derived vasoconstrictor, endothelin-l (ET-1), has been demonstrated in patients with SSc. 6 7 In view of the biological actions of ET-1, this finding has been interpreted as a possible pathogenic mechanism in SSc, rather than a simple consequence of microvascular damage.7 In particular, it has been suggested that ET-1 may favour the initiation of vascular and perivascular fibrosis in the pulmonary and systemic vascular beds, thus leading to a progressive increase in blood pressure in both. 7 Although possible confirmation of this intriguing hypothesis has recently come from the in vitro demonstration of a profibrotic action of ET-1 in human perivascular fibroblasts,7 little is known of the influence of pulmonary or systemic hypertension on circulating ET-1 concentrations in patients affected by SSc.
We have investigated this by measuring plasma ET-1 levels in these patients and evaluating the relationship between changes in peptide concentrations and both pulmonary and systemic arterial pressures.
Patients and methods
Forty eight patients (41 women, seven men; mean age 47-2 (SD 5 5) years) were randomly selected from presenting outpatients, solely on the basis of a definite diagnosis of SSc that met with American Rheumatism Association (ARA) criteria,' willingness to participate, and absence of both diabetes mellitus and renal failure. In particular, serum creatinine was < 1 15 ,umol/l and creatinine clearance was >1-5 ml/s in all patients. All patients were white, non-smokers (n = 37) or ex-smokers (n = 11), and had no concomitant diseases. Patients were treated with D-penicillamine (n = 11), calcium antagonists (n = 15), ketanserin (n = 9), captopril (n = 14), and prazosin (n = 8). Nine patients were taking combined treatment (D-penicillamine and calcium antagonists, or calcium antagonists and captopril). All treatments were interrupted one week before the study. , containing 0 9% sodium chloride, 0-05% sodium azide and 0 5% bovine serum albumin). The chromatography resulted in a single peak of immunoreactive ET, corresponding exactly with the position of elution of human ET-1 standard and '25I-ET-1. ET-1 immunoreactivity was then assayed on reconstituted samples using a sensitive radioimmunoassay (Peninsula Laboratories, Belmont, CA). Human ET-1 (Peptide Institute, Osaka, Japan) was used as standard. Interassay and intra-assay variations were <10%. Mean recovery of human ET-1 standard using our method was 85%. Cross reactivity of ET-1 antibody with ET-2 and ET-3 was <7%, according to the supplier.
Other routine laboratory tests were carried out in our laboratories by standard methods.
ECHOCARDIOGRAPHY
Echocardiographic studies were performed using commercially available equipment, using left parasternal and apical approaches. A complete M mode and two dimensional evaluation was performed in both patients and controls. Functioning of all cardiac valves was also investigated by colour Doppler. Conventionally, flows directed toward the transducer were codified in red and flows directed away from the transducer were coded blue. Green colour (variance) was added to represent flow turbulence. Great care was taken in detecting tricuspid regurgitation: the transducer was manipualted to obtain the best visualisation of valvular insufficiency by colour-flow Doppler mapping and a continuous wave Doppler cursor was positioned parallel to flow. If the angle of intersection between Doppler cursor and tricuspid regurgitant flow was >20°, attempts to detect tricuspid insufficiency were repeated from a subcostal transducer position. In some cases, the subject was asked to take a deep breath and to remain in inspiratory apnoea: in this way, it was usually possible to obtain an optimal representation of tricuspid regurgitant flow and to place the Doppler cursor in parallel with it. The same manoeuvres were then repeated using the non-imaging, high sensitivity Pedoff transducer guided by audio and visual signals. In our experience, the latter transducer permits the detection of better defined Doppler envelopes and higher velocities than combined imaging and continuous wave Doppler probe. The maximum velocity of the signal tracing observed on at least two consecutive cardiac cycles was used for calculation of the pressure gradient. Optimal signals were assumed to be oriented parallel to the direction of regurgitation and thus a flow angle correction for velocity was not used. 12 also had pulmonary hypertension. Plasma ET-1 levels were similar in both groups (1-65 (0-18) pg/ml and 1-65 (0-38) pg/ml, respectively, NS). All control subjects had normal blood pressures (1255 (3 5)/825 (3 5) mm Hg) (p < 0-0001 v all patients with SSc).
We were able to identify four subgroups in our study population (table 2): 1 1 patients with neither pulmonary nor systemic hypertension, 14 with pulmonary hypertension alone, 1 1 with systemic hypertension alone, and 12 with both these conditions. Plasma ET-1 levels were substantially similar in each subgroup (fig 2) .
The presence of diffuse rather than the limited form of SSc did not influence plasma ET-1 levels: circulating peptide concentrations were 1 62 (0 39) pg/ml in patients with diffuse SSc (n=40) and 1-68 (0-14) pg/ml in those with limited SSc (n = 8) (p = 0 904; NS).
Plasma ET-1 levels were not correlated with pulmonary artery systolic pressure (fig 3) 
Values are mean (SD). PH = Pulmonary hypertension; SH = systemic hypertension; PH + SH = pulmonary and systemic hypertension; SS = no pulmonary or systemic hypertension; C = control subjects. pressure'1'7 or systemic systolic, diastolic, and mean arterial pressures.1>20 Furthermore, our findings disagree with previous reportsi416 describing the presence of increased plasma ET-1 in patients affected by primary or secondary pulmonary hypertension.
One possible explanation for this discrepancy may be the small size of our study population.2' However, another recent report in patients with SSc with either echo-Doppler or invasive evidence of pulmonary hypertension also failed to demonstrate increased circulating ET-1 in comparison with patients with SSc and normal pulmonary pressures. 22 Nevertheless, in that study,22 the prevalence of pulmonary hypertension was low (20%) compared with expected values (ranging from 33% with invasive to 48% with non-invasive methods).23 24 Two other important factors seem to deserve particular attention. First, an arteriovenous ET-1 concentration difference has been reported in patients with pulmonary hypertension,'5 therefore assay of ET-1 in blood taken from an antecubital vein might not reflect the effective concentration of ET-1 in the pulmonary circulation. Second, endothelial cells in culture release more than 80% of newly generated ET-1 into the abluminal side, while only 20% is secreted into the luminal one,25 thus supporting the hypothesis that circulating ET-1 might not reflect the local concentration of ET-1 in the pulmonary vessel wall. Therefore, although our findings require confirmation by measurement of ET-1 in blood from the small pulmonary arteries and veins and from the right atria, they may indicate a more complex interaction between ET-1 and the pulmonary vasculature, prompting a general reassessment of the role of ET-1 in pulmonary hypertension.
In '6 could have overestimated circulating ET-1 levels by evaluating big-ET-1 in addition to ET-1. In agreement with this hypothesis, increased levels of plasma big-ET-1 have been described in patients with pulmonary hyper-32 tension,3 and were significantly greater than those of ET-1. 32 In the current study, we separated ET-1 from the other ET isoforms and precursors by high performance liquid chromatography. With this method, the levels of circulating ET-1 from both control subjects and patients with SSc were two to 10-fold lower than those previously described in patients with pulmonary hypertension.'1'6 It could therefore be speculated also that the lack of correlation between plasma ET-1 and pulmonary pressures may simply reflect the use of a more appropriate method for ET-1 assay.
In this context, it is interesting that systemic hypertension also was not associated with particular changes in plasma ET-1 levels in patients with SSc. However, we do not find this surprising, as a causal relationship between increased ET-1 concentrations in plasma and 
